This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O'Malley, B. W. Articles by Woo, S. L. C. Search for Related Content PubMed PubMed Citation Articles by O'Malley, B. W., Jr. Articles by Woo, S. L. C.

Combination Gene Therapy for Oral Cancer in a Murine Model¹

Johns Hopkins University, Baltimore, Maryland 21203 [B. W. O., K. A. C., D. L.], and Baylor College of Medicine, Houston, Texas 77030 [S-H. C., M. R. S., S. L. C. W.]

Combination therapy involving adenovirus-mediated transfer of the genes for herpes thymidine kinase (tk) and murine interleukin 2 (mIL-2) was used to treat head and neck cancer in C3H/HeJ mice. Tumors were generated by transcutaneous injection of 5 x 10⁵ murine squamous carcinoma cells into the floor of the mouth of these syngeneic mice. After 1 week, recombinant adenoviral vectors containing both therapeutic and control genes in various combinations were injected directly into the established tumors, and subsequently all mice were administered ganciclovir twice daily (25 mg/kg) for 6 days. Animals receiving either tk alone or tk + mIL-2 demonstrated significant tumor regression compared to mIL-2 alone or control vector-treated mice (P < 0.008). Mice receiving both tk + mIL-2, however, also demonstrated a significantly greater regression of tumors compared to those treated with tk alone (P < 0.008), indicating a synergistic effect of the combination gene therapy. This synergism was confirmed in survival studies because tk + mIL-2-treated mice showed increased survivals (P = 0.0002). Clinical and microscopic exam of regional surrounding tissues and distant organs showed no evidence of cytotoxicity for representative animals in each experimental group. These results suggest that combination tk and mIL-2 gene therapy may provide a powerful new modality for the treatment of head and neck cancer.

¹ Supported in part by a grant from the Markey Foundation.

² To whom requests for reprints should be addressed, at Department of Otolaryngology-HNS, Johns Hopkins University, P. O. Box 41402, Baltimore, MD 21203-6402.

Received 2/ 6/96. Accepted 3/11/96.

This article has been cited by other articles:

				S. Xi and J.R. Grandis Gene Therapy for the Treatment of Oral Squamous Cell Carcinoma Journal of Dental Research, January 1, 2003; 82(1): 11 - 16. [Abstract] [Full Text] [PDF]

				D. Li, B. Ronson, M. Guo, S. Liu, J. S. Bishop, D. A. Van Echo, and B. W. O'Malley Jr. Interleukin 2 Gene Transfer Prevents NKG2D Suppression and Enhances Antitumor Efficacy in Combination with Cisplatin for Head and Neck Squamous Cell Cancer Cancer Res., July 15, 2002; 62(14): 4023 - 4028. [Abstract] [Full Text] [PDF]

				K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1441 - 1451. [Abstract] [Full Text] [PDF]

				K. T. Robbins The Evolving Role of Combined Modality Therapy in Head and Neck Cancer Arch Otolaryngol Head Neck Surg, March 1, 2000; 126(3): 265 - 269. [Full Text] [PDF]

				D. Li, L. Duan, P. Freimuth, and B. W. O'Malley Jr. Variability of Adenovirus Receptor Density Influences Gene Transfer Efficiency and Therapeutic Response in Head and Neck Cancer Clin. Cancer Res., December 1, 1999; 5(12): 4175 - 4181. [Abstract] [Full Text] [PDF]

				J. L. Blackwell, C. R. Miller, J. T. Douglas, H. Li, P. N. Reynolds, W. R. Carroll, G. E. Peters, T. V. Strong, and D. T. Curiel Retargeting to EGFR Enhances Adenovirus Infection Efficiency of Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, August 1, 1999; 125(8): 856 - 863. [Abstract] [Full Text] [PDF]

				R. Zhang, F. H. Straus, and L. J. DeGroot Effective Genetic Therapy of Established Medullary Thyroid Carcinomas with Murine Interleukin-2: Dissemination and Cytotoxicity Studies in a Rat Tumor Model Endocrinology, May 1, 1999; 140(5): 2152 - 2158. [Abstract] [Full Text]

				X. Danthinne, K. Aoki, A. L. Kurachi, G. J. Nabel, and E. G. Nabel Combination Gene Delivery of the Cell Cycle Inhibitor p27 with Thymidine Kinase Enhances Prodrug Cytotoxicity J. Virol., November 1, 1998; 72(11): 9201 - 9207. [Abstract] [Full Text] [PDF]

				R. Zhang, K. Minemura, and L. J. De Groot Immunotherapy for Medullary Thyroid Carcinoma by a Replication-Defective Adenovirus Transducing Murine Interleukin-2 Endocrinology, February 1, 1998; 139(2): 601 - 608. [Abstract] [Full Text] [PDF]

				D. A. Sewell, D. Li, L. Duan, W. H. Westra, and B. W. O'Malley Jr Safety of In Vivo Adenovirus-Mediated Thymidine Kinase Treatment of Oral Cancer Arch Otolaryngol Head Neck Surg, December 1, 1997; 123(12): 1298 - 1302. [Abstract] [PDF]

				B. W. O’Malley Jr., D. A. Sewell, D. Li, K.-i. Kosai, S.-H. Chen, S. L.C. Woo, and L. Duan The Role of Interleukin-2 in Combination Adenovirus Gene Therapy for Head and Neck Cancer Mol. Endocrinol., June 1, 1997; 11(6): 667 - 673. [Abstract] [Full Text]